<?xml version="1.0" encoding="UTF-8"?>
<p>In 
 <xref ref-type="fig" rid="biomolecules-09-00726-f002">Figure 2</xref>, we illustrate the major effect of type I IFNs in the regulation of cellular energy and lipid metabolism from recent and early studies [
 <xref rid="B88-biomolecules-09-00726" ref-type="bibr">88</xref>,
 <xref rid="B89-biomolecules-09-00726" ref-type="bibr">89</xref>,
 <xref rid="B90-biomolecules-09-00726" ref-type="bibr">90</xref>,
 <xref rid="B91-biomolecules-09-00726" ref-type="bibr">91</xref>,
 <xref rid="B92-biomolecules-09-00726" ref-type="bibr">92</xref>,
 <xref rid="B93-biomolecules-09-00726" ref-type="bibr">93</xref>,
 <xref rid="B94-biomolecules-09-00726" ref-type="bibr">94</xref>,
 <xref rid="B95-biomolecules-09-00726" ref-type="bibr">95</xref>,
 <xref rid="B96-biomolecules-09-00726" ref-type="bibr">96</xref>,
 <xref rid="B97-biomolecules-09-00726" ref-type="bibr">97</xref>,
 <xref rid="B98-biomolecules-09-00726" ref-type="bibr">98</xref>,
 <xref rid="B99-biomolecules-09-00726" ref-type="bibr">99</xref>,
 <xref rid="B100-biomolecules-09-00726" ref-type="bibr">100</xref>,
 <xref rid="B101-biomolecules-09-00726" ref-type="bibr">101</xref>,
 <xref rid="B102-biomolecules-09-00726" ref-type="bibr">102</xref>,
 <xref rid="B103-biomolecules-09-00726" ref-type="bibr">103</xref>,
 <xref rid="B104-biomolecules-09-00726" ref-type="bibr">104</xref>,
 <xref rid="B105-biomolecules-09-00726" ref-type="bibr">105</xref>]. For energy metabolism, type I IFNs enhance glucose uptake in both mouse embryonic fibroblasts and human plasmacytoid dendritic cells (pDCs) [
 <xref rid="B18-biomolecules-09-00726" ref-type="bibr">18</xref>,
 <xref rid="B88-biomolecules-09-00726" ref-type="bibr">88</xref>,
 <xref rid="B89-biomolecules-09-00726" ref-type="bibr">89</xref>,
 <xref rid="B90-biomolecules-09-00726" ref-type="bibr">90</xref>,
 <xref rid="B91-biomolecules-09-00726" ref-type="bibr">91</xref>]. Similarly, IFN-induced increases of glycolysis, oxidative phosphorylation, and ATP production derived from the TCA cycle have been observed in multiple human cells including macrophages, DCs, T cells, keratinocytes, and some cancer cell lines [
 <xref rid="B18-biomolecules-09-00726" ref-type="bibr">18</xref>,
 <xref rid="B80-biomolecules-09-00726" ref-type="bibr">80</xref>,
 <xref rid="B81-biomolecules-09-00726" ref-type="bibr">81</xref>,
 <xref rid="B91-biomolecules-09-00726" ref-type="bibr">91</xref>,
 <xref rid="B92-biomolecules-09-00726" ref-type="bibr">92</xref>,
 <xref rid="B93-biomolecules-09-00726" ref-type="bibr">93</xref>,
 <xref rid="B94-biomolecules-09-00726" ref-type="bibr">94</xref>]. Particularly in macrophages, IFNs also act on the cellular TCA cycle to stimulate the synthesis of reactive oxygen species (ROS) and itaconic acid to augment the cell antimicrobial activity against engulfed pathogens [
 <xref rid="B82-biomolecules-09-00726" ref-type="bibr">82</xref>,
 <xref rid="B89-biomolecules-09-00726" ref-type="bibr">89</xref>,
 <xref rid="B95-biomolecules-09-00726" ref-type="bibr">95</xref>,
 <xref rid="B96-biomolecules-09-00726" ref-type="bibr">96</xref>,
 <xref rid="B97-biomolecules-09-00726" ref-type="bibr">97</xref>,
 <xref rid="B98-biomolecules-09-00726" ref-type="bibr">98</xref>]. The IFN suppression of lipid metabolism is multifaceted, and can occur by directly repressing the synthesis of fatty acid (FA) and cholesterol in HeLa cells, and by regulating the upstream mediators of AMPK and mTOR complex in several human and mouse cells [
 <xref rid="B99-biomolecules-09-00726" ref-type="bibr">99</xref>,
 <xref rid="B100-biomolecules-09-00726" ref-type="bibr">100</xref>,
 <xref rid="B101-biomolecules-09-00726" ref-type="bibr">101</xref>,
 <xref rid="B102-biomolecules-09-00726" ref-type="bibr">102</xref>,
 <xref rid="B103-biomolecules-09-00726" ref-type="bibr">103</xref>,
 <xref rid="B104-biomolecules-09-00726" ref-type="bibr">104</xref>]. Similarly, in livestock cells, we determined that IFNs exert potent antiviral and immunomodulatory activities through interaction with the metabolic system [
 <xref rid="B76-biomolecules-09-00726" ref-type="bibr">76</xref>]. The expression of IFNs is regulated either by the nutrient sensor mTOR, or by direct reprograming of the lipid metabolic pathways. Thus, a mutual relationship between IFN production and metabolic core processes is manifested in antiviral responses [
 <xref rid="B4-biomolecules-09-00726" ref-type="bibr">4</xref>,
 <xref rid="B76-biomolecules-09-00726" ref-type="bibr">76</xref>,
 <xref rid="B99-biomolecules-09-00726" ref-type="bibr">99</xref>,
 <xref rid="B100-biomolecules-09-00726" ref-type="bibr">100</xref>,
 <xref rid="B101-biomolecules-09-00726" ref-type="bibr">101</xref>,
 <xref rid="B102-biomolecules-09-00726" ref-type="bibr">102</xref>,
 <xref rid="B103-biomolecules-09-00726" ref-type="bibr">103</xref>]. For example, type I IFNs induce the synthesis of 25-hydroxycholesterol (25HC), a potent metabolite in cholesterol metabolism that exerts a broad antiviral activity and suppressive effect in production of inflammatory cytokines including IL-1 and TNF-α [
 <xref rid="B82-biomolecules-09-00726" ref-type="bibr">82</xref>,
 <xref rid="B86-biomolecules-09-00726" ref-type="bibr">86</xref>,
 <xref rid="B96-biomolecules-09-00726" ref-type="bibr">96</xref>]. In addition, type I IFNs also promote the cross-membrane import of cholesterol and FA into the cells and strengthen membrane rigidity in multiple human cells [
 <xref rid="B80-biomolecules-09-00726" ref-type="bibr">80</xref>,
 <xref rid="B81-biomolecules-09-00726" ref-type="bibr">81</xref>]. Potentially, lipogenesis is a sub-effect of the IFN antiviral activity via increase of 25HC synthesis and cholesterol/FA import, particularly under a situation of persistent viral infections. Plasma ceramide and dihydroceramide levels are a biomarker of insulin resistance and obesity, and molecular manipulation of body ceramide to control obesity was illuminated by a recent elegant study [
 <xref rid="B104-biomolecules-09-00726" ref-type="bibr">104</xref>]. Notably, other reports indicated that both IFN-γ and IFN-β are potent to regulate ceramide metabolism [
 <xref rid="B104-biomolecules-09-00726" ref-type="bibr">104</xref>,
 <xref rid="B105-biomolecules-09-00726" ref-type="bibr">105</xref>]. Taken together, the effective IFN response during acute phases of antiviral responses may actually suppress meta-inflammation and reduce energy flow toward lipogenesis in adipocytes. However, the prolonged IFN responses during chronic viral infections might be an adipogenic drive and could lead to immune suppression mostly in obesity patients (see 
 <xref ref-type="fig" rid="biomolecules-09-00726-f003">Figure 3</xref> and the next section) [
 <xref rid="B80-biomolecules-09-00726" ref-type="bibr">80</xref>,
 <xref rid="B81-biomolecules-09-00726" ref-type="bibr">81</xref>].
</p>
